EGLN1 and acute myeloid leukemia: With the aim of developing a PHD inhibitor suitable for AML treatment, we identified a PHD-specific hydrophobic pocket close to the entrance of the PHD2 active site and proposed that targeting this pocket may lead to PHD-selective inhibition.